Printer Friendly

COMPANY INFORMATION
QLT Inc. 101-887 Great Northern Way Vancouver, BC V5T 4T5 Tel: (604) 707-7000 Toll-free: (800) 663-5486 Fax: (604) 707-7001 Contact Name Cameron R. Nelson Industry Biotechnology		Key Executives Robert L. Butchofsky, CEO Cameron R. Nelson, CFO Develops and commercializes proprietary pharmaceutical products for the treatment of eye diseases. The company's lead product is Visudyne® for the treatment of wet age-related macular degeneration (wet AMD). Visudyne® was co-developed with Novartis Pharma AG and is marketed and sold in more than 80 countries. Development is focused on ophthalmic product candidates.
FP ADVISOR COVERAGE QLT Inc. • FP Corporate Analyzer • FP Directory of Directors • FP Corporate Surveys • FP Investor Reports • FP Predecessor & Defunct • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 364,726 Angiotech Pharmaceuticals, Inc. 319,113 AEterna Zentaris Inc. 72,153 QLT Inc. 48,042 GLG Life Tech Corporation 41,884 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF JULY 29/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX/QLT NASDAQ/QLTI $5.73 $6.80 on June 7/10 $3.35 on Oct. 21/09 n.a. n.a. n.a. 0.62 Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap (000s) 15,629 n.a. US$ -0.56 June 30/10 66.09% -7.54% -11.34% $300,604
ANNUAL FINANCIALS Periods ended: 12m Dec. 31/09 12m Dec. 31/08 12m Dec. 31/07 US$000s US$000s US$000s Operating revenue 42,106 124,140 127,905 Net income 99,434 134,891 (109,997) Total assets 419,637 491,758 548,987 US$ US$ US$ Earnings per share* 1.77 1.81 (1.47) % % % Return on equity (9.69) 5.31 (41.96)   * Common A Reported in accordance with U.S. GAAP
TRAILING 12-MONTH VALUES Periods ended: June 30/10 June 30/09 US$000s US$000s Operating revenue 45,687 112,973 Net income 91,891 162,730 US$ US$ Earnings per share 1.64 2.23   A Reported in accordance with U.S. GAAP

COMPANY NEWS

Results for 'QLT Inc.' from past 30 days: No hits. (Links are to articles.)